Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 789-794

  Aoyagi, Haruhiko ^a   Iida, Satoru ^a   Uetake, Hiroyuki ^a   Ishikawa, Toshiaki ^a   Takagi, Yoko ^a   Kobayashi, Hirotoshi ^a   Higuchi, Tetsuro ^a   Yasuno, Masamichi ^a   Enomoto, Masayuki ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Methylation; Mutation; Prognosis

Indexed keywords

AKT1 PROTEIN; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN; PROTEIN MINT1; PROTEIN MINT2; PROTEIN MINT3; PROTEIN MLH1; PROTEIN P16; PROTEIN PIK3CA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; EPIGENETICS; FEMALE; GENE MUTATION; GENETICS; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COLORECTAL NEOPLASMS; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS;

EID: 79551578831     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1118     Document Type: Article

References (46)

1. Ricchi P, Zaeeilli R, Di Palma A and Acquaviva AM: Non-steroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 88: 803-807, 2003.
2. Kobayashi H, Mochizuki H, Sugihara K, et al: Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 141: 67-75, 2007.
3. Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
4. Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50: 113-130, 2007.
5. Ogino S and Goel A: Molecular classification and correlates in colorectal cancer. J Mol Diagn 10: 13-27, 2008.
6. Sjoblom T, Jones S, Wood LD, et al: The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274, 2006.
7. Nosho K, Kawasaki T, Ohnishi M, et al: PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10: 534-541, 2008.
8. Nagasaka T, Koi M, Kloor M, et al: Mutations in both KRAS and BRAF may contribute to methylator phenotype in colon cancer. Gastroenterology 134: 1950-1960, 2008.
9. Samowitz WS, Sweeney C, Herrick J, et al: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65: 6063-6070, 2005.
10. Oliviera C, Velho S, Moutinho C, et al: KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26: 158-163, 2007.
11. Moroni M, Veronese S, Benvenuti S, et al: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286, 2005.
12. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
13. Cunningham D and Wong R: Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol 26: 5668-5670, 2008.
14. Seth R, Crook S, Ibrahem S, et al: Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the RAS/RAF signaling pathway in advanced colorectal cancer. Gut 58: 1234-1241, 2009.
15. Tanaka H, Deng G, Matsuzaki K, et al: BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than nonmucinous colorectal cancer. Int J Cancer 118: 2765-2771, 2006.
16. Oikonomou E and Pintzas A: Cancer genetics of sporadic colorectal cancer: BRAF and PIK3CA mutations, their impact on signaling and novel targeted therapies. Anticancer Res 26: 1077-1084, 2006.
17. Kato S, Iida S, Higchi T, et al: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121: 1771-1778, 2007.
18. Feinberg AP and Tycko B: The history of cancer epigenetics. Nat Rev Cancer 4: 143-153, 2004.
19. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
20. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
21. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687-692, 2001.
22. Verma M and Strivastava S: Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 3: 755-763, 2002.
23. Eads CA, Danenberg KD, Kawakami K, et al: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32, 2000.
24. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001.
25. Barault L, Veyrie N, Jooste V, et al: Mutations in the RASMAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122: 2255-2259, 2008.
26. Davies H, Bingnell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
27. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934, 2002.
28. Brim H, Mokarram P, Naghibalhossaini F, et al: Impact on BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in population based study. Mol Cancer 7: 68, 2008.
29. Lee S, Cho NY, Choi M, Yoo EJ, Kim JH and Kang GH: Clinico-pathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 58: 104-113, 2008.
30. Chang SC, Lin JK, Yang SH, Wang HS, Li AFY and Chi CW: Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 118: 1721-1727, 2008.
31. Yuen ST, Davis H, Chan TL, et al: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62: 6451-6455, 2002.
32. Vilkin A, Niv Y, Nagasaka T, et al: Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Cancer 115: 760-769, 2009.
33. Slattery ML, Curtin K, Levin TR, et al: Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 120: 656-663, 2006.
34. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ and Soderkvist P: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25: 527-533, 2004.
35. Carpen JD, Faber AL, Horn C, et al: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-445, 2007.
36. Kim MS, Jeong EG and Lee SH: Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98: 1533-1535, 2008.
37. Bleeker FE, Felicioni L, Buttitta F, et al: AKT1E17K in human solid tumours. Oncogene 27: 5648-5650, 2008.
38. Toyota M, Ahuja N, Ohe-Toyota M, Baylin SB and Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686, 1999. (Pubitemid 29354851)
39. Goel A, Nagasaka T, Arnold CN, et al: The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132: 127-138, 2007.
40. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M and Fuchs CS: Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 9: 305-314, 2007.
41. Shannon BA and Lacopetta BJ: Methylation of the hMLH1, p16 and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. Cancer Lett 167: 91-97, 2001.
42. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870-6875, 1998.
43. Veigl ML, Kasturi L, Olechnowicz J, et al: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 95: 8698-8702, 1998.
44. Wettergren Y, Odin E, Nilsson S, Carlsson G and Gustavsson B: p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer. Int Mol Med 14: 412-421, 2008.
45. Shen L, Toyota M, Kondo Y, et al: Integrated genetic and epigenetic analysis identifies three different subclass of colon cancer. Proc Natl Acad Sci USA 104: 18654-18659, 2007.
46. Ogino S, Nosho K, Kirkner GJ, et al: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58: 90-96, 2009.